분화 갑상선 암의 추적 관찰에서 진단적 I-123 전신 스캔의 최적 영상 시점: 동일 환자에서 6시간과 24시간 영상의 비교

Optimal Imaging Time for Diagnostic I-123 Whole Body Scan in the Follow-up of Patients with Differentiated Thyroid Cancer: Comparison between 6- and 24-Hour Images of the Same Subjects

  • 이홍제 (경북대학교 의학전문대학원 핵의학교실) ;
  • 이상우 (경북대학교 의학전문대학원 핵의학교실) ;
  • 송봉일 (경북대학교 의학전문대학원 핵의학교실) ;
  • 장성민 (경북대학교 의학전문대학원 핵의학교실) ;
  • 서지형 (경북대학교 의학전문대학원 핵의학교실) ;
  • 유정수 (경북대학교 의학전문대학원 핵의학교실) ;
  • 안병철 (경북대학교 의학전문대학원 핵의학교실) ;
  • 이재태 (경북대학교 의학전문대학원 핵의학교실)
  • Lee, Hong-Je (Department of Nuclear Medicine, Kyungpook National University School of Medicine) ;
  • Lee, Sang-Woo (Department of Nuclear Medicine, Kyungpook National University School of Medicine) ;
  • Song, Bong-Il (Department of Nuclear Medicine, Kyungpook National University School of Medicine) ;
  • Kang, Sung-Min (Department of Nuclear Medicine, Kyungpook National University School of Medicine) ;
  • Seo, Ji-Hyoung (Department of Nuclear Medicine, Kyungpook National University School of Medicine) ;
  • Yoo, Jeong-Soo (Department of Nuclear Medicine, Kyungpook National University School of Medicine) ;
  • Ahn, Byeong-Cheol (Department of Nuclear Medicine, Kyungpook National University School of Medicine) ;
  • Lee, Jae-Tae (Department of Nuclear Medicine, Kyungpook National University School of Medicine)
  • 발행 : 2009.04.30

초록

목적: I-123 진단 스캔은 분화 갑상선암 환자의 추적 관찰에 주요한 역할을 하고 있다. 이 연구는 분화 감상선암 환자의 재발과 전이를 발견하는데 있어서 5시간과 24시간 I-123진단 스캔을 비교하여 최적 영상 시점을 찾고자 하였다. 대상 및 방법: 분화 갑상선 암으로 진단되어 갑상선 절제술과 고용량 방사성옥소 치료를 받은 후 추적 관찰 중에 185 MBq(5 mCi)의 I-123으로 6시간과 24시간 진단적 전신 스캔을 시행한 498명의 환자들(남:녀=55:443, 연령: $47.6{\pm}12.9$ 세)을 대상으로 하였다. 같은 시기에 모든 환자들에서 혈액 검사와 경부 초음파를 시행하였다. 추가적인 방사성옥소 치료를 시행한 40명의 환자에서는 치료 후 I-131 스캔을 얻었으며 I-123 진단 스캔과 비교하였다. 결과: 총 498명의 환자들 중 440명(88.4%)에서 6시간과 24시간 영상이 일치하는 결과를 보였으며, 58명(11.6%)에서는 두 영상의 결과가 일치하지 않았다. 불일치를 보이는 58명 중 6시간 영상에서만 이상 섭취를 보이는 31명의 환자들은 모두 위양성 소견을 보였으며, 24시간 영상에서만 이상 섭취를 보이는 12명의 환자들에서는 4명의 잔류 갑상선 조직과 3명의 경부 림프절 전이가 확인되었고, 24시간 영상에서 더 뚜렷한 소견을 보이는 15명 중에서는 2명의 잔류 갑상선 조직과 1명의 경부 림프절 전이가 확인되었다. 추가적인 방사성옥소 치료가 시행된 40명 중 13명에서 두 영상이 불일치를 보였는데, 6시간 영상에서만 이상 섭취가 관찰되는 경우는 모두 위양성 소견을 보였고 24시간 영상은 치료 후 I-131 스캔과 일치하는 결과를 보였다. 결론: 갑상선 환자의 전이 및 재발의 추적 관찰에 있어서 I-123 24시간 영상이 6시간 영상에 비해 진단의 정확도가 더 우수하고 위양성을 줄일 수 있었다.

Purpose: To determine optimal imaging time for diagnostic I-123 whole body scan in the follow-up of patients with differentiated thyroid cancer(DTC), we compared the image quality of 6- and 24-hour images of the same subjects. Materials and Methods: Four hundred ninety-eight patients(M:F = 55:443, Age $47.6{\pm}12.9$ years) with DTC who had undergone total thyroidectomy and I-131 ablation therapy underwent diagnostic whole body scanning 6 hour and 24 hour after oral ingestion of 185 MBq(5 mCi) of I-123. Serum thyroglobulin measurement and ultrasonography of the neck were performed at the time of imaging. In 40 patients underwent additional I-131 therapy, post-therapy I-131 images were obtained and compared with diagnostic I-123 images. Results: In 440 patients(88.4%), 6- and 24-hour diagnostic I-123 images were concordant, and 58 patients(11.6%) showed discordant findings. Among 58 discordant patients, 31 patients showed abnormal tracer uptake on only 6-hour image, which turned out false-positive findings in all cases. In 12 patients with positive findings on only 24-hour image, remnant thyroid tissue(4 patients) and cervical lymph node metastasis(3 patients) were presented. Among 40 patients underwent additional I-131 therapy, 6-hour and 24-hour images were discordant in 13 patients. All 5 patients with abnormal uptake on only 6-hour image revealed false-positive results, whereas most of 24-hour images were concordant with post-therapy I-131 images. Conclusion: I-123 imaging at 24-hour could reduce false-positive findings and improve diagnostic accuracy, compared with 6-hour image in the follow-up of patient with DTC.

키워드

참고문헌

  1. Bae SK Recent advances in radioiodine therapy for thyroid cancer. Nucl Med Mol Imaging 2006;40:132-40
  2. Sarkar SD, Kalapparambath TP, Palestro CJ. Comparison of $^{123}$I and $^{131}$I for whole-body imaging in thyroid cancer. J Nucl Med 2002;43:632-4
  3. Alzahrani AS, Bakheet S, Al Mandil M, Al-Hajjaj A, Almahfouz A, Al Haj A $^{123}$I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post $^{131}$I therapy whole body scanning. J Din Endocrinol Metab 2001;86:5294-300 https://doi.org/10.1210/jc.86.11.5294
  4. Siddiqi A, Foley RR, Britton KE, Sibtain A, Plowman PN, Grossman AB, et al. The role of $^{123}$I -diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to $^{131}$I -scanning: avoidance of negative therapeutic uptake due to stunning. Clin Endocrinol (Oxf) 2001;55:515-21 https://doi.org/10.1046/j.1365-2265.2001.01376.x
  5. Mandel SJ, Shankar LK, Benard F, Yamamoto A, Alavi A. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 2001;26:6-9 https://doi.org/10.1097/00003072-200101000-00002
  6. Anderson GS, Fish S, Nakhoda K, Zhuang H, Alavi A, Mandel SJ. Comparison of I-123 and I-131 for whole-body imaging after stimulation by recombinant human thyrotropin: a preliminary report. Clin Nucl Med 2003;28:93-6 https://doi.org/10.1097/00003072-200302000-00001
  7. Urhan M, Dadparvar S, Mavi A, Houseni M, Chamroonrat W, Alavi A, et al. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging 2007;34:1012-7 https://doi.org/10.1007/s00259-006-0341-x
  8. Gerard SK, Cavalieri RR I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours. Clin Nucl Med 2002;27:1-8 https://doi.org/10.1097/00003072-200201000-00001
  9. Shankar LK, Yamamoto AJ, Alavi A, Mandel SJ. Comparison of $^{123}$I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. J Nucl Med 2002;43:72-6
  10. Kim JY, Moon SJ, Kim KR, Sohn CY, Oh JJ. Dietary iodine intake and urinary iodine excretion in normal Korean adults. Yonsei Medical Journal 1998;39:355-62 https://doi.org/10.3349/ymj.1998.39.4.355
  11. Lee HY, Chung JK, Kang WJ, So Y, Lee DS, Lee MC. Comparing I-123 scan and I-131 scan for evaluate post therapy state in thyroid cancer [abstract]. Korean J Nucl Med 2004;38:461
  12. Yan W, Roach PJ, Bautovich GJ, Learoyd DL, Robinson BG. Timing of iodine-123 scintigraphy following use of recombinant human thyrotropin in differentiated thyroid carcinoma. Clin Nucl Med 2007;32:375-7 https://doi.org/10.1097/01.rlu.0000259616.75495.b8
  13. Britton KE, Foley RR, Chew SL. Should high hTg levels in the absence of iodine uptake be treated? Eur J Nucl Med Mol Imaging 2003;30:794-5 https://doi.org/10.1007/s00259-003-1139-8
  14. Britton KE, Granowska M Radioimmlliloscintigraphy in tumour identification. Cancer Surv 1987;6:247-67
  15. Lee JW, Lee HY, Oh SW, Kim SK, Jeong KW, Kim SW, et al. Evaluation of usefulness of radio-iodine SPECT/CT in differentiated thyroid cancer. Nucl Med Mol Imaging 2007;41:350-8
  16. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002;87:1490-8 https://doi.org/10.1210/jc.87.4.1490
  17. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002;87:1499-501 https://doi.org/10.1210/jc.87.4.1499
  18. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003;88:3668-73 https://doi.org/10.1210/jc.2002-021925
  19. Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 2003;97:90-6 https://doi.org/10.1002/cncr.11031
  20. Mazzaferri EL, Robbins RJ, Spencer CA, Bravennan LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-41 https://doi.org/10.1210/jc.2002-021702